Get the Stockscreener App
28.48
1.10%
0.31
Pre-market:
28.56
0.08
+0.28%
Roivant Sciences Ltd stock is traded at $28.48, with a volume of 4.08M.
It is up +1.10% in the last 24 hours and down -3.56% over the past month.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
See More
Previous Close:
$28.17
Open:
$27.975
24h Volume:
4.08M
Relative Volume:
0.66
Market Cap:
$20.38B
Revenue:
$13.31M
Net Income/Loss:
$-1.01B
P/E Ratio:
-24.37
EPS:
-1.1685
Net Cash Flow:
$-766.86M
1W Performance:
+0.53%
1M Performance:
-3.56%
6M Performance:
+76.67%
1Y Performance:
+187.97%
1-Day Range:
$27.93
$28.78
1-Week Range:
$27.40
$28.78
52-Week Range:
$9.24
$30.33
Roivant Sciences Ltd Stock (ROIV) Company Profile
Name
Roivant Sciences Ltd
Sector
Industry
Phone
441-295-5950
Address
7TH FLOOR, 50 BROADWAY, LONDON
Compare ROIV vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
28.48 | 20.16B | 13.31M | -1.01B | -766.86M | -1.1685 |
VRTX
Vertex Pharmaceuticals Inc
|
446.78 | 112.92B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
767.85 | 81.99B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
800.50 | 48.82B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.28 | 43.66B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.42 | 34.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-20-26 | Initiated | Bernstein | Outperform |
| Sep-02-25 | Initiated | Citigroup | Buy |
| Jul-10-25 | Resumed | Goldman | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Jan-05-24 | Initiated | Piper Sandler | Overweight |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Oct-17-23 | Initiated | Guggenheim | Buy |
| Jun-08-23 | Initiated | BofA Securities | Neutral |
| Oct-27-22 | Initiated | JP Morgan | Overweight |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-29-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-15-21 | Initiated | Goldman | Buy |
| Nov-08-21 | Initiated | H.C. Wainwright | Buy |
| Oct-28-21 | Initiated | Citigroup | Buy |
| Oct-26-21 | Initiated | Cowen | Outperform |
| Oct-26-21 | Initiated | Jefferies | Buy |
| Oct-26-21 | Initiated | Truist | Buy |
View All
Roivant Sciences Ltd Stock (ROIV) Latest News
Analysts Are Bullish on Top Healthcare Stocks: Roivant Sciences (ROIV), Boston Scientific (BSX) - The Globe and Mail
Roivant Sciences Ltd. (ROIV) Stock forecasts - Yahoo Finance UK
Capricorn Fund Managers Ltd Buys 247,000 Shares of Roivant Sciences Ltd. $ROIV - MarketBeat
Roivant Sciences Ltd. (ROIV) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Roivant Sciences Ltd. (ROIV) Discusses Brepocitinib Program Expansion and Phase III Batoclimab Data UpdateSlideshow (NASDAQ:ROIV) 2026-04-04 - Seeking Alpha
ROIV PE Ratio & Valuation, Is ROIV Overvalued - Intellectia AI
ROIV | Roivant Sciences Ltd. Common Executive Compensation - Quiver Quantitative
Roivant Sciences (ROIV) Is Up 6.8% After Mixed Autoimmune Trial UpdatesHas The Bull Case Changed? - simplywall.st
Roivant Sciences Ltd. (ROIV) stock price, news, quote and history - Yahoo Finance UK
Roivant Sciences Ltd. Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
Should Brepocitinib’s New Trials and Batoclimab’s Setback Require Action From Roivant Sciences (ROIV) Investors? - Yahoo Finance
Roivant (NASDAQ: ROIV) executive settles RSU taxes with shares - Stock Titan
Immunovant Batoclimab Flops in Phase 3 TED as Roivant Expands Brepocitinib Into LPP - Yahoo Finance
Roivant Shrugs Off Batoclimab Phase III Failure in TED - Citeline News & Insights
Roivant Sciences Adds Brepocitinib LPP Trial as Batoclimab Misses Phase III TED Endpoint - Yahoo Finance
Roivant (Nasdaq: ROIV) shows $4.3B cash and mixed late-stage trial results - Stock Titan
Scarring hair-loss disease gets drug trial with no approved therapy - Stock Titan
Roivant Sciences (ROIV) executive settles CVARs and RSUs into shares - Stock Titan
Roivant Sciences Ltd. (ROIV) Stock Forecasts - Yahoo Finance
(ROIV) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Movement Recap: Is Roivant Sciences Ltd forming a bullish divergence2026 Patterns & Long-Term Capital Growth Strategies - baoquankhu1.vn
CEO Change: Is Roivant Sciences Ltd a potential multi bagger2026 Pullbacks & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Volume Summary: Is Roivant Sciences Ltd stock risky to hold now2026 Retail & Community Consensus Stock Picks - baoquankhu1.vn
250,468 Shares in Roivant Sciences Ltd. $ROIV Acquired by Exchange Traded Concepts LLC - MarketBeat
Roivant Sciences Insider Sold Shares Worth $1,921,500, According to a Recent SEC Filing - MarketScreener
Roivant Sciences Ltd (ROIV) Stock Price Quote Today & Current Price Chart - Capital.com
Roivant Sciences Ltd (ROIV) Stock Price Quote Today & Current Price Chart | Capital.com Australia - Capital.com
Roivant Sciences (NASDAQ: ROIV) director exercises 70K options, sells 70K shares - Stock Titan
Aug Sentiment: Is Roivant Sciences Ltd backed by strong institutional buyingStock Surge & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Assessing Roivant Sciences (ROIV) Valuation After Brepocitinib Priority Review And Phase 3 VALOR Success - Sahm
Cantor Fitzgerald reiterates Roivant Sciences stock rating By Investing.com - Investing.com India
Gains Recap: Should I hold or sell Roivant Sciences Ltd nowMarket Weekly Review & AI Driven Stock Movement Reports - baoquankhu1.vn
Sentiment Watch: Is Roivant Sciences Ltd a potential multi bagger2026 Decliners & High Accuracy Swing Entry Alerts - baoquankhu1.vn
ROIV Technical Analysis & Stock Price Forecast - Intellectia AI
Bernstein initiates coverage of Roivant Sciences Ltd. (ROIV) with an outperform rating - msn.com
New England Journal of Medicine publishes positive phase 3 valor trial results of brepocitinib in dermatomyositis - marketscreener.com
NEJM study: rare muscle-skin disease drug beat placebo in Phase 3 - Stock Titan
Aug Ideas: Whats the fair value of Roivant Sciences Ltd stockTrade Exit Report & Community Verified Watchlist Alerts - baoquankhu1.vn
Should Roivant’s Moderna Settlement Shift Investor Focus to Pipeline Execution Risks for Roivant Sciences (ROIV)? - simplywall.st
Can Roivant Sciences Ltd sustain earnings growthEarnings Performance Report & AI Forecasted Stock Moves - baoquankhu1.vn
Big Money Moves: Can Roivant Sciences Ltd sustain earnings growthProduct Launch & Weekly Watchlist for Hot Stocks - baoquankhu1.vn
Vanguard realignment leads to separate reports for Roivant (ROIV) - Stock Titan
Bernstein Initiates Coverage of Roivant Sciences Ltd. (ROIV) with an Outperform Rating - Insider Monkey
Roivant Sciences (ROIV) CFO reports RSU tax-withholding of 1,546 shares - Stock Titan
Assenagon Asset Management S.A. Purchases 6,877,348 Shares of Roivant Sciences Ltd. $ROIV - marketbeat.com
Roivant Sciences, Genevant, Arbutus, and Moderna Settle International Patent Litigation – Key Terms and Confidentiality Details - Minichart
Roivant Sciences (ROIV) soars 19.4% as pipeline drugs progress - MSN
Roivant secures FDA priority review for dermatomyositis treatment - MSN
Risk Analysis: Is Roivant Sciences Ltd backed by strong institutional buyingBreakout Watch & High Conviction Investment Ideas - baoquankhu1.vn
Roivant Sciences Ltd. (NASDAQ:ROIV) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
(ROIV) Risk Channels and Responsive Allocation - Stock Traders Daily
Roivant Sciences Ltd Stock (ROIV) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.57%
0.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):